Telehealth is marketed as borderless and is not. A patient who moves, travels for work, or splits the year between two addresses runs into a structural feature of US medical regulation that most providers mention only in the small print: a clinician’s authority to prescribe is tied to the state where the patient is located, not to where the clinician sits.
This produces practical problems that patients discover at inconvenient moments, and it is worth understanding before signing up rather than after.
The basic rule
Medical licensure in the United States is administered by individual states. A clinician licensed in one state may treat patients located in that state. To treat a patient located elsewhere, the clinician generally needs authority in that other state as well.
Telehealth does not change this. The question is not where the clinician is, it is where the patient is at the time of the consultation. That is why intake forms ask for a state and why the answer sometimes ends the process.
Telehealth providers address the problem by building networks of clinicians licensed across multiple states, which is why coverage varies between services and why a provider available to a patient’s neighbour may not be available to them.
What it means for a patient who moves
The awkward case is the established patient. Someone on a stable treatment plan who relocates may find that their prescribing clinician has no authority in the new state.
Depending on the provider’s network, this resolves in one of three ways. The patient is reassigned to a clinician licensed in the new state and continues with minimal disruption. The provider does not operate in the new state and the relationship ends. Or, most disruptively, the transition is handled slowly and the patient experiences a gap in supply.
For treatments where continuity matters, a gap is not a neutral event. In the GLP-1 category specifically, interruption and restart often means revisiting the titration process rather than resuming where things left off, which is a clinical setback as well as an administrative one.
What it means for travel
Short trips are generally not the issue people imagine. The relevant moment is the consultation and the prescribing, not every day of the year. A patient who consults from their home state and travels afterwards is in a different position from one attempting to begin treatment while away.
The complication is refills and adjustment conversations, which are consultations. A patient who needs an adjustment while spending three months in another state may find the conversation cannot happen as expected.
Anyone who genuinely splits time between two states should raise it at intake rather than discovering the constraint mid-treatment.
The questions to ask before starting
Which states does this provider actually cover? Not “do you serve my state” but the full list, because it determines what happens if circumstances change.
What happens if I move? Specifically: is there a reassignment process, how long does it take, and is there a supply gap.
Can I have a consultation while temporarily in another state? Providers differ and the answer is rarely on the website.
Is my prescribing clinician licensed in my state, or is the company? The licence sits with the clinician. A company operating nationally does not mean every clinician can treat every patient.
Providers vary in how plainly they set this out. HealSend, which prescribes semaglutide online through US-licensed clinicians, checks the patient’s state during intake and states on its own pages that it prescribes only where its clinician network is licensed. That is the correct structure, and a patient should confirm the specifics for their own state rather than assuming national coverage from national marketing.
Why this matters more in this category than most
Two features of GLP-1 and dual-receptor treatment make the licensure question sharper than it would be for a one-off prescription.
Treatment is long-running, which means the probability of a patient’s circumstances changing during it is high.
And it involves regular clinical contact rather than a single consultation, because titration and side effect management are ongoing. Each of those contacts is subject to the same constraint.
A patient starting a treatment they expect to continue for a year should therefore ask about state coverage as a structural question about the provider, not as a formality about today.
The practical takeaway
The borderless framing of telehealth is a marketing simplification of a system that remains state-based. For most patients most of the time this is invisible. For patients who move, travel extensively or split their year, it is the single most likely thing to interrupt their treatment, and it is entirely predictable in advance.
Asking four questions at intake costs nothing and avoids the version of this problem that gets discovered during a refill.Content
